Balentine LLC’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.63M | Buy |
6,466
+734
| +13% | +$158K | 0.06% | 64 |
|
|
2026
Q1 | $1.25M | Sell |
5,732
-61
| -1% | -$13.5K | 0.05% | 70 |
|
|
2025
Q4 | $1.32M | Buy |
5,793
+146
| +3% | +$33.3K | 0.05% | 67 |
|
|
2025
Q3 | $1.31M | Buy |
5,647
+264
| +5% | +$53.8K | 0.05% | 68 |
|
|
2025
Q2 | $999K | Buy |
5,383
+374
| +7% | +$69.5K | 0.04% | 69 |
|
|
2025
Q1 | $1.05M | Sell |
5,009
-511
| -9% | -$99.3K | 0.04% | 68 |
|
|
2024
Q4 | $981K | Sell |
5,520
-5,322
| -49% | -$978K | 0.04% | 57 |
|
|
2024
Q3 | $2.14M | Buy |
10,842
+5,056
| +87% | +$944K | 0.08% | 40 |
|
|
2024
Q2 | $992K | Sell |
5,786
-33,385
| -85% | -$5.53M | 0.05% | 56 |
|
|
2024
Q1 | $7.13M | Buy |
39,171
+3,348
| +9% | +$577K | 0.21% | 39 |
|
|
2023
Q4 | $5.55M | Buy |
35,823
+6,857
| +24% | +$1,000K | 0.18% | 48 |
|
|
2023
Q3 | $4.32M | Buy |
28,966
+5,090
| +21% | +$747K | 0.14% | 51 |
|
|
2023
Q2 | $3.22M | Buy |
23,876
+2,472
| +12% | +$363K | 0.11% | 65 |
|
|
2023
Q1 | $3.41M | Sell |
21,404
-5,995
| -22% | -$917K | 0.11% | 61 |
|
|
2022
Q4 | $4.43M | Buy |
27,399
+2,302
| +9% | +$353K | 0.15% | 46 |
|
|
2022
Q3 | $3.37M | Sell |
25,097
-57,654
| -70% | -$8.27M | 0.13% | 50 |
|
|
2022
Q2 | $12.7M | Buy |
82,751
+68,159
| +467% | +$10.4M | 0.46% | 26 |
|
|
2022
Q1 | $2.37M | Buy |
14,592
+2,724
| +23% | +$396K | 0.08% | 69 |
|
|
2021
Q4 | $1.61M | Buy |
11,868
+2,838
| +31% | +$335K | 0.06% | 58 |
|
|
2021
Q3 | $974K | Sell |
9,030
-60
| -0.7% | -$6.86K | 0.04% | 66 |
|
|
2021
Q2 | $1.02M | Sell |
9,090
-648
| -7% | -$73K | 0.04% | 42 |
|
|
2021
Q1 | $1.05M | Buy |
9,738
+1,166
| +14% | +$125K | 0.05% | 39 |
|
|
2020
Q4 | $918K | Sell |
8,572
-679
| -7% | -$65.3K | 0.04% | 40 |
|
|
2020
Q3 | $810K | Buy |
9,251
+6,147
| +198% | +$579K | 0.04% | 39 |
|
|
2020
Q2 | $305K | Sell |
3,104
-11
| -0.4% | -$969 | 0.02% | 67 |
|
|
2020
Q1 | $237K | Buy |
3,115
+1,004
| +48% | +$85.5K | 0.02% | 55 |
|
|
2019
Q4 | $187K | Buy |
2,111
+393
| +23% | +$32.6K | 0.01% | 78 |
|
|
2019
Q3 | $130K | Buy |
1,718
+1,139
| +197% | +$78.1K | 0.01% | 85 |
|
|
2019
Q2 | $42K | Sell |
579
-848
| -59% | -$66.7K | ﹤0.01% | 123 |
|
|
2019
Q1 | $115K | Buy |
1,427
+82
| +6% | +$6.71K | 0.01% | 84 |
|
|
2018
Q4 | $124K | Buy |
1,345
+1,269
| +1,670% | +$112K | 0.01% | 72 |
|
|
2018
Q3 | $7K | Hold |
76
| – | – | ﹤0.01% | 203 |
|
|
2018
Q2 | $7K | Buy |
+76
| New | +$7.42K | ﹤0.01% | 109 |
|
|
2018
Q1 | – | Sell |
-805
| Closed | -$78K | – | 62 |
|
|
2017
Q4 | $78K | Buy |
805
+16
| +2% | +$1.51K | 0.01% | 221 |
|
|
2017
Q3 | $70K | Buy |
789
+84
| +12% | +$6.39K | 0.01% | 222 |
|
|
2017
Q2 | $51K | Hold |
705
| – | – | ﹤0.01% | 241 |
|
|
2017
Q1 | $46K | Hold |
705
| – | – | ﹤0.01% | 231 |
|
|
2016
Q4 | $44K | Sell |
705
-867
| -55% | -$52.9K | ﹤0.01% | 223 |
|
|
2016
Q3 | $99K | Buy |
1,572
+874
| +125% | +$56.6K | 0.01% | 121 |
|
|
2016
Q2 | $43K | Sell |
698
-28
| -4% | -$1.71K | 0.01% | 159 |
|
|
2016
Q1 | $41K | Sell |
726
-120
| -14% | -$6.69K | 0.01% | 117 |
|
|
2015
Q4 | $50K | Sell |
846
-640
| -43% | -$36.9K | 0.01% | 156 |
|
|
2015
Q3 | $81K | Buy |
1,486
+749
| +102% | +$48.8K | 0.01% | 116 |
|
|
2015
Q2 | $50K | Buy |
737
+640
| +660% | +$41.8K | 0.01% | 147 |
|
|
2015
Q1 | $6K | Buy |
+97
| New | +$5.86K | ﹤0.01% | 309 |
|
Other funds holding ABBV
Balentine LLC's ABBV Position: Q2 2026 in Review
Balentine LLC increased its AbbVie (ABBV) stake by 13% in Q2 2026, buying an estimated $158K and bringing the position to 6,466 shares worth $1.63M. The position accounts for 0.06% of the portfolio, ranked #64.
Balentine LLC first reported a position in ABBV in Q1 2015 and has held it in 45 quarters since. The position peaked at $12.7M in Q2 2022. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Balentine LLC held 6,466 shares of AbbVie worth $1.63M as of Q2 2026.
- Balentine LLC bought 734 AbbVie shares in Q2 2026, an estimated $158K.
- AbbVie made up 0.06% of Balentine LLC's portfolio in Q2 2026, its #64 holding.
- Balentine LLC first reported a position in AbbVie in Q1 2015 and has held it in 45 quarters since.
- Balentine LLC's AbbVie position peaked at $12.7M in Q2 2022.
- 4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Balentine LLC's 13F filing for Q2 2026, filed 6 Aug 2026.